Ventricular tachycardia cost effectiveness of therapy: Difference between revisions
Created page with "Category:Needs content Category:Disease Category:Electrophysiology Category:Cardiology Category:Emergency medicine Category:Intensive care medicine" |
Hudakarman (talk | contribs) No edit summary |
||
| (5 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Ventricular tachycardia}} | |||
== Overview == | |||
Based on a randomized clinical trial evidence, [[Catheter ablation]] of VT is unlikely to be cost-effective compared with [[antiarrhythmic drug]] (AAD) therapy. However, more detailed and better designed studies are needed to provide more informed cost-effectiveness analyses.<br /> | |||
== Cost effectiveness of therapy == | |||
Evidence from a randomized clinical trial has shown that [[Catheter ablation]] of VT is unlikely to be cost-effective compared with [[antiarrhythmic drug]] (AAD) therapy. However, better designed studies with more details and more frequent quality of life assessments are required to provide more informed cost-effectiveness analyses<ref name="pmid32076562">{{cite journal| author=Chen Y, Gomes M, Garcia JV, Hunter RJ, Chow AW, Dhinoja M | display-authors=etal| title=Cost-effectiveness of ablation of ventricular tachycardia in ischaemic cardiomyopathy: limitations in the trial evidence base. | journal=Open Heart | year= 2020 | volume= 7 | issue= 1 | pages= e001155 | pmid=32076562 | doi=10.1136/openhrt-2019-001155 | pmc=6999675 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32076562 }}</ref> | |||
==References== | |||
{{Reflist|2}} | |||
{{WH}} | |||
{{WS}} | |||
[[Category:Needs content]] | [[Category:Needs content]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
| Line 5: | Line 20: | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
[[Category:Intensive care medicine]] | [[Category:Intensive care medicine]] | ||
[[Category:Up-To-Date cardiology]] | |||
[[Category:Up-To-Date]] | |||
Latest revision as of 00:00, 5 March 2020
|
Ventricular tachycardia Microchapters |
|
Differentiating Ventricular Tachycardia from other Disorders |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Ventricular tachycardia cost effectiveness of therapy On the Web |
|
FDA on Ventricular tachycardia cost effectiveness of therapy |
|
Ventricular tachycardia cost effectiveness of therapy in the news |
|
Blogs on Ventricular tachycardia cost effectiveness of therapy |
|
to Hospitals Treating Ventricular tachycardia cost effectiveness of therapy |
|
Risk calculators and risk factors for Ventricular tachycardia cost effectiveness of therapy |
Overview
Based on a randomized clinical trial evidence, Catheter ablation of VT is unlikely to be cost-effective compared with antiarrhythmic drug (AAD) therapy. However, more detailed and better designed studies are needed to provide more informed cost-effectiveness analyses.
Cost effectiveness of therapy
Evidence from a randomized clinical trial has shown that Catheter ablation of VT is unlikely to be cost-effective compared with antiarrhythmic drug (AAD) therapy. However, better designed studies with more details and more frequent quality of life assessments are required to provide more informed cost-effectiveness analyses[1]
References
- ↑ Chen Y, Gomes M, Garcia JV, Hunter RJ, Chow AW, Dhinoja M; et al. (2020). "Cost-effectiveness of ablation of ventricular tachycardia in ischaemic cardiomyopathy: limitations in the trial evidence base". Open Heart. 7 (1): e001155. doi:10.1136/openhrt-2019-001155. PMC 6999675 Check
|pmc=value (help). PMID 32076562 Check|pmid=value (help).